Whitebox Advisors’s Esperion Therapeutics ESPR Stock Holding History

Whitebox Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-30,182	Closed	-$49.8K	–	288
2024 Q3	$49.8K	Buy	+30,182	New	+$60.9K	﹤0.01%	181

Other funds holding ESPR

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Whitebox Advisors's ESPR Position: Q4 2024 in Review

Whitebox Advisors sold out of Esperion Therapeutics (ESPR) in Q4 2024, closing a stake of 30,182 shares — an estimated $49.8K sold.

Whitebox Advisors first reported a position in ESPR in Q3 2024 and held it in 1 quarter. The position peaked at $49.8K in Q3 2024. 189 funds tracked by Wall St. Rank hold ESPR as of Q4 2024.

Whitebox Advisors reported no remaining Esperion Therapeutics position as of Q4 2024 after selling out during the quarter.
Whitebox Advisors sold 30,182 Esperion Therapeutics shares in Q4 2024, an estimated $49.8K.
Whitebox Advisors first reported a position in Esperion Therapeutics in Q3 2024 and held it in 1 quarter.
Whitebox Advisors's Esperion Therapeutics position peaked at $49.8K in Q3 2024.
189 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2024.

Based on Whitebox Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.